IPP Bureau
Biocon to obtain approval for diabetes drug, Liraglutide in UK
By IPP Bureau - March 28, 2024
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Tata Elxsi and Dräger collaborate to drive critical care innovation in India
By IPP Bureau - March 28, 2024
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
lpca Laboratories enters into Technology Transfer Agreement with Omexa Formulary
By IPP Bureau - March 28, 2024
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Briefs: Alkem Laboratories and Zydus Lifesciences
By IPP Bureau - March 28, 2024
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
Dr Reddy's partners with Sanofi India to distribute vaccine brands in India
By IPP Bureau - March 28, 2024
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Asahi Songwon Colors acquires remaining 22% stake in Atlas Life Sciences
By IPP Bureau - March 28, 2024
Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%
Caplin Group commences operations of Rs. 150 crore oncology facility
By IPP Bureau - March 28, 2024
The facility will manufacture tablets, capsules, and injections for the oncology segment
EC approves Merck’s Keytruda plus chemotherapy as neoadjuvant treatment for non-small cell lung cancer
By IPP Bureau - March 28, 2024
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
Sanofi and Cipla enters into distribution partnership to expand reach of CNS portfolio in India
By IPP Bureau - March 27, 2024
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
Data privacy, security and ethical challenges must for adoption of GenAI in healthcare: PwC India
By IPP Bureau - March 27, 2024
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
Apollo Cancer Centres heralds a new era in breast cancer surgery
By IPP Bureau - March 27, 2024
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder
By IPP Bureau - March 27, 2024
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
By IPP Bureau - March 27, 2024
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Warren Remedies commences commercial production of APIs
By IPP Bureau - March 26, 2024
